CTA
DRNA

Carillon Tower Advisers’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Carillon Tower Advisers’s Portfolio DRNA Stock Details DRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$24.7M Sell
1,120,359
-56,154
-5% -$1.24M 0.15% 203
2020
Q3 		$21.2M Buy
1,176,513
+56,154
+5% +$1.16M 0.28% 126
2020
Q2 		$28.5M Hold
1,120,359
– – 0.22% 146
2020
Q1 		$19.4M Hold
1,120,359
– – 0.19% 175
2019
Q4 		$24.7M Hold
1,120,359
– – 0.16% 218
2019
Q3 		$16.1M Buy
+1,120,359
New +$16M 0.11% 280

Other funds holding DRNA

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Carillon Tower Advisers's DRNA Position: Q4 2020 in Review

Carillon Tower Advisers reduced its Dicerna Pharmaceuticals, Inc. (DRNA) stake by 4.8% in Q4 2020, selling an estimated $1.24M and leaving 1,120,359 shares worth $24.7M. The position accounts for 0.15% of the portfolio, ranked #203.

Carillon Tower Advisers first reported a position in DRNA in Q3 2019 and has held it in 6 quarters since. The position peaked at $28.5M in Q2 2020. 174 funds tracked by Wall St. Rank hold DRNA as of Q4 2020.

  • Carillon Tower Advisers held 1,120,359 shares of Dicerna Pharmaceuticals, Inc. worth $24.7M as of Q4 2020.
  • Carillon Tower Advisers sold 56,154 Dicerna Pharmaceuticals, Inc. shares in Q4 2020, an estimated $1.24M.
  • Dicerna Pharmaceuticals, Inc. made up 0.15% of Carillon Tower Advisers's portfolio in Q4 2020, its #203 holding.
  • Carillon Tower Advisers first reported a position in Dicerna Pharmaceuticals, Inc. in Q3 2019 and has held it in 6 quarters since.
  • Carillon Tower Advisers's Dicerna Pharmaceuticals, Inc. position peaked at $28.5M in Q2 2020.
  • 174 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.